Atea Pharmaceuticals Inc Ordinary Shares AVIR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
-
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
Trading Information
- Previous Close Price
- $3.33
- Day Range
- $3.39–3.49
- 52-Week Range
- $2.77–4.60
- Bid/Ask
- $3.46 / $3.47
- Market Cap
- $292.10 Mil
- Volume/Avg
- 121,430 / 223,058
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 75
- Website
- https://www.ateapharma.com
Comparables
Valuation
|
Metric
|
AVIR
|
TVTX
|
CLYM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.61 | 76.88 | 1.55 |
Price/Sales | — | 6.59 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
AVIR
TVTX
CLYM
Financial Strength
|
Metric
|
AVIR
|
TVTX
|
CLYM
|
|---|---|---|---|
Quick Ratio | 18.87 | 2.89 | 59.65 |
Current Ratio | 19.02 | 3.04 | 60.41 |
Interest Coverage | — | −35.20 | — |
Quick Ratio
AVIR
TVTX
CLYM
Profitability
|
Metric
|
AVIR
|
TVTX
|
CLYM
|
|---|---|---|---|
Return on Assets (Normalized) | −23.62% | −9.03% | −45.38% |
Return on Equity (Normalized) | −25.11% | −47.00% | −46.50% |
Return on Invested Capital (Normalized) | −29.21% | −13.68% | −46.38% |
Return on Assets
AVIR
TVTX
CLYM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jdzxlmqgq | Bwjy | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Skjbvgcdz | Pvclfyf | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gjycvxvxc | Xlfgx | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qxhhccwpc | Tsjrc | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Wljsxgqkn | Jzpkx | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Pbccphdq | Prt | $29.2 Bil | |||
| Moderna Inc
MRNA
| Bqynljmq | Ygqlf | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Hntjpdf | Wpp | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xmxtwhbf | Lhjvgs | $13.2 Bil | |||
| Incyte Corp
INCY
| Gjvgztb | Djpsyc | $13.0 Bil |
United States